In the last decade, the therapeutic options in the first-line treatments of advanced ovarian cancer have been implemented by the combination of carboplatin/paclitaxel with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab [3,4,5,6], and with the recent addition of the poly ADP-ribose polymerase (PARP) inhibitor olaparib [7]. Here, VEGFA is linked to ovarian cancer.